论文部分内容阅读
目的探讨盐酸贝那普利辅助治疗早期糖尿病肾病的临床疗效。方法 72例早期糖尿病肾病患者,随机分为观察组和对照组,各36例。观察组予以盐酸贝那普利,对照组予以糖尿病常规治疗,比较两组治疗后实验室指标和临床疗效。结果观察组治疗后尿素氮(BUN)为(6.03±2.13)mmol/L低于对照组的(8.09±2.71)mmol/L,肌酐清除率(Cr)为(114.23±11.94)μmol/L高于对照组的(94.76±11.96)μmol/L,尿素(Ur)为(384.29±49.87)μmol/L低于对照组的(425.17±52.36)μmol/L,24 h尿蛋白量(0.26±0.04)g低于对照组的(0.44±0.03)g,C反应蛋白(CRP)为(2.83±1.74)mg/L低于对照组的(3.67±1.75)mg/L,差异具有统计学意义(P<0.05);观察组显效率为88.9%和总有效率97.2%高于对照组的55.6%和72.2%,差异具有统计学意义(P<0.05)。结论盐酸贝那普利辅助治疗早期糖尿病肾病临床效果好,实验室指标恢复快,适合临床广泛推广。
Objective To investigate the clinical efficacy of benazepril in the treatment of early diabetic nephropathy. Methods 72 patients with early diabetic nephropathy were randomly divided into observation group and control group, 36 cases in each. The observation group was treated with benazepril hydrochloride, and the control group was given routine diabetes treatment. The laboratory indexes and clinical efficacy were compared between the two groups. Results The BUN in the observation group was significantly lower than that in the control group (6.03 ± 2.13 mmol / L vs 8.09 ± 2.71 mmol / L vs 114.23 ± 11.94 μmol / L (94.76 ± 11.96) μmol / L and 384.29 ± 49.87 μmol / L in the control group were lower than those in the control group (425.17 ± 52.36) μmol / L and 24 h urinary protein (0.26 ± 0.04) g (0.44 ± 0.03) g and (2.83 ± 1.74) mg / L of CRP in the control group were lower than those in the control group (3.67 ± 1.75 mg / L, P <0.05) ). The effective rate of the observation group was 88.9% and the total effective rate was 97.2%, which was significantly higher than that of the control group (55.6% and 72.2%, P <0.05). Conclusion Benazepril hydrochloride adjuvant therapy for early diabetic nephropathy clinical effect is good, rapid recovery of laboratory indicators, suitable for clinical promotion.